Non-alcoholic fatty liver disease (NAFLD) is a prevalent and progressive liver disease, affecting approximately 25% of the global population. This article provides a comprehensive overview of NAFLD, its pathophysiology, diagnosis, and management.
NAFLD is characterized by the accumulation of excess fat in the liver, unrelated to alcohol consumption. It is closely associated with metabolic syndrome, obesity, insulin resistance, and type 2 diabetes. The disease spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma.
NAFLD is often asymptomatic and may be incidentally diagnosed during routine blood tests or imaging studies. Liver biopsy remains the gold standard for diagnosing NASH and assessing fibrosis. However, non-invasive tests like elastography and serum biomarkers are increasingly used due to their safety and convenience.
The primary management strategy for NAFLD involves lifestyle modifications, including weight loss, healthy diet, and regular exercise. Pharmacological interventions are considered for patients with NASH or significant fibrosis. Currently, Vitamin E and Pioglitazone have shown some benefits in these patients. Several new drugs targeting different pathophysiological pathways are under investigation.
Healthcare professionals play a crucial role in the early detection and management of NAFLD. They should educate patients about the importance of lifestyle changes and monitor them regularly for disease progression. Multidisciplinary approach involving hepatologists, dietitians, and endocrinologists may be beneficial in managing this complex disease.
NAFLD is a significant global health issue with potential serious outcomes. Understanding its pathophysiology, diagnosis, and management strategies is essential for healthcare professionals to effectively manage this disease and prevent its progression.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation